Lv4
686 积分 2025-11-14 加入
Unorthodox Applications of Diethylaminosulfur Trifluoride and its Analogs in Organic Synthesis
30分钟前
待确认
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
6个月前
已完结
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
6个月前
已完结
Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
11个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
11个月前
已完结
Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism
11个月前
已完结
The current and future landscape of Bruton’s tyrosine kinase inhibitors in allergy
1年前
已完结
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
1年前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
1年前
已完结
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors
1年前
已完结